The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...
Recursion outlines $375M 2026 cash OpEx guidance while advancing first Genentech neuroscience target
"Over the past year, we have reached an important inflection point. We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Christopher Winrow, PhD, Recursion’s vice president of neuroscience, inside the company’s lab. Recursion marked a milestone in its up to $12 billion artificial intelligence (AI) collaboration with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results